|
시장보고서
상품코드
2032430
비알코올성 지방간염 시장 : 약제 유형, 질환 원인, 판매 채널, 최종 사용자 및 지역별(2026-2034년)Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2026-2034 |
||||||
세계의 비알코올성 지방간염(NASH) 시장 규모는 2025년에 24억 달러에 이르렀습니다. 향후 IMARC Group은 2026-2034년 CAGR 22.06%로 성장하여 2034년까지 149억 달러에 이를 것으로 예측했습니다. NASH의 유병률 증가, 조기 진단 및 치료에 대한 인식 증가, 인공지능(AI) 및 머신러닝(ML) 기술의 통합이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
비알코올성 지방간염(NASH)은 인슐린 저항성, 과체중, 대사증후군으로 인해 발생하는 진행성 비알코올성 지방간질환(NAFLD)을 말합니다. 증상으로는 피로감, 쇠약감, 체중 감소, 황달, 피부 가려움증, 거미줄 같은 혈관, 간 비대, 집중력 저하, 체액 저류, 통증과 부종과 같은 복부 불편감 등이 있습니다. 진단에는 신체검사, 혈액검사, 간 생검, 자기공명영상(MRI), 초음파 검사, 컴퓨터단층촬영(CT) 검사 등 여러 가지 방법이 사용됩니다. NASH 치료에는 약물 치료, 간이식, 그리고 규칙적인 운동과 건강한 식습관 등 다양한 생활습관 개선이 포함됩니다. 이러한 치료법은 간 지방 축적 감소, 간 기능 개선, 염증 억제, 간 손상을 최소화하는 데 도움이 될 수 있습니다. 또한 환자의 삶의 질을 향상시키고 장기적인 예후를 개선하며 비만이나 고혈압과 같은 다른 건강 문제를 더 잘 관리할 수 있습니다.
비알코올성 지방간염(NASH) 시장 동향 :
유전적 요인, 운동 부족, 건강에 해로운 식습관, 비만, 2형 당뇨병으로 인한 NASH 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 이에 따라 증상 완화, 수명 연장, 조기 사망 예방, 간 건강 개선 및 전반적인 건강 증진을 목적으로 NASH 치료가 환자들에게 널리 받아들여지고 있으며, 이는 시장 성장의 원동력이 되고 있습니다. 또한, 의료비 절감, 간 이식의 필요성 제거, 고혈압, 심혈관 질환(CVD), 암, 간경변, 간부전 등 향후 합병증을 예방하기 위한 NASH의 조기 진단 및 치료에 대한 대중의 인식이 높아지면서 시장 성장에 탄력을 받고 있습니다. 또한, MRI, 일과성 탄성파 검사(TE)와 같은 비침습적 영상진단 기술을 활용한 NASH 모니터링 및 진단은 환자의 편의성을 높이고, 치료 순응도를 높이며, 합병증 위험을 줄이고, 임상적 결과를 개선하여 시장 성장에 긍정적인 영향을 미치고 있습니다. 여기에 인공지능(AI)과 머신러닝(ML)을 통합하여 개인 맞춤형 치료법을 개발하고, 진단 정확도를 높이며, 질병의 진행을 예측하는 노력도 시장 성장을 견인하고 있습니다. 또한, 양질의 치료에 대한 접근성을 제공하고 첨단 치료법 개발을 지원하기 위한 다양한 정부 주도 이니셔티브가 시행되면서 시장 성장을 가속하고 있습니다. 이 외에도 고령 인구 증가, 의료비 증가, 활발한 연구개발(R&:D) 활동, 헬스케어 산업의 괄목할 만한 성장, 비침습적 치료법에 대한 수요 증가 등의 요인이 시장 성장을 견인할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 비알코올성 지방간염 시장
제6장 시장 분석 : 약제 유형별
제7장 시장 분석 : 질환 원인별
제8장 시장 분석 : 세일즈 채널별
제9장 시장 분석 : 최종 사용자별
제10장 시장 분석 : 지역별
제11장 촉진, 억제 및 기회
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
JHS 26.05.18The global non-alcoholic steatohepatitis (NASH) market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2034, exhibiting a growth rate (CAGR) of 22.06% during 2026-2034. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.
Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI) , ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.
NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET TRENDS:
The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Drug Type Insights:
- Vitamin E and Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
Disease Cause Insights:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Sales Channel Insights:
- Hospital Pharmacy
- Online Providers
- Retail Pharmacy
End User Insights:
- Hospitals
- Clinics
- Homecare Settings
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Non-Alcoholic Steatohepatitis (NASH) Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Type
- 6.1 Vitamin E and Pioglitazone
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Ocaliva
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Elafibranor
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Selonsertib
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Cenicriviroc
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Disease Cause
- 7.1 Hypertension
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Heart Disease
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 High Blood Lipid
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Type 2 Diabetes
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Obesity
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Sales Channel
- 8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Online Providers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Retail Pharmacy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Homecare Settings
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Algernon Pharmaceuticals
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Galmed Pharmaceuticals Ltd
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.3 Intercept Pharmaceuticals Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Zydus Lifesciences Limited
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.1 Algernon Pharmaceuticals
